Because a portion of patients with CLL acquire new aberrations during the course of the disease, we presumed that a deficiency in the TP53 tumor suppressor gene could promote oxidation-mediated mutagenesis, thereby contributing to accelerated malignant progression. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.